VSAR - Long Opportunity

Versartis Inc, had a clinical trial that failed, same deal with AXON and few others, but they still have 3 or 4 trials pending. Dont think it would fall lower. If they have trials left but not that good at these kind of plays. Keep an eye on this one forsure. Might just hold a small lot, 52 week high was 24 $.
Beyond Technical AnalysisbiotechinvestinvestmentLONGnasdaqnyseStocksTrend AnalysisS&P/TSX CompositeVSARWave Analysis

Penafian